Health-care cost reduction resulting from primary-care allergy testing in children in Italy.

Niklas Zethraeus, Carl Johan Petersson, Massimiliano Dozzi, Magnus P. Borres, Giulio Vignati, Alessandro Fiocchi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Allergy places a considerable cost burden on society. Specific immunoglobulin E (spIgE) testing may improve the management of allergy patients. There is therefore a reason to quantify the economic consequences of the use of spIgE testing in the diagnosis of allergic conditions. METHODS: The expected costs of spIgE testing versus no-testing were calculated using a clinical decision model based on a prospective clinical trial performed in primary care. RESULTS: The expected costs per patient over 2 years decreased from 802 euros in the "no-test strategy" to 560 euros in the spIgE "test strategy". Cost savings persisted even after assumptions about the prevalence of allergy and the prices of medications were changed. The "test strategy" increased the percentage of patients correctly diagnosed from 54 to 87%. CONCLUSIONS: spIgE testing of children with respiratory and/or skin problems in primary care in Italy reduces overall costs to society. These cost savings mostly result from a reduction in the use of medications, particularly corticosteroids. The study indicates that spIgE testing of all children with respiratory and/or skin symptoms would be a cost-effective strategy.

Original languageEnglish
Pages (from-to)61
Number of pages1
JournalItalian Journal of Pediatrics
Volume36
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Health Care Costs
Immunoglobulin E
Italy
Primary Health Care
Hypersensitivity
Costs and Cost Analysis
Cost Savings
Skin
Adrenal Cortex Hormones
Economics
Clinical Trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Health-care cost reduction resulting from primary-care allergy testing in children in Italy. / Zethraeus, Niklas; Petersson, Carl Johan; Dozzi, Massimiliano; Borres, Magnus P.; Vignati, Giulio; Fiocchi, Alessandro.

In: Italian Journal of Pediatrics, Vol. 36, No. 1, 2010, p. 61.

Research output: Contribution to journalArticle

Zethraeus, Niklas ; Petersson, Carl Johan ; Dozzi, Massimiliano ; Borres, Magnus P. ; Vignati, Giulio ; Fiocchi, Alessandro. / Health-care cost reduction resulting from primary-care allergy testing in children in Italy. In: Italian Journal of Pediatrics. 2010 ; Vol. 36, No. 1. pp. 61.
@article{85b5ffd3bbac4062be0007bdaf690519,
title = "Health-care cost reduction resulting from primary-care allergy testing in children in Italy.",
abstract = "BACKGROUND: Allergy places a considerable cost burden on society. Specific immunoglobulin E (spIgE) testing may improve the management of allergy patients. There is therefore a reason to quantify the economic consequences of the use of spIgE testing in the diagnosis of allergic conditions. METHODS: The expected costs of spIgE testing versus no-testing were calculated using a clinical decision model based on a prospective clinical trial performed in primary care. RESULTS: The expected costs per patient over 2 years decreased from 802 euros in the {"}no-test strategy{"} to 560 euros in the spIgE {"}test strategy{"}. Cost savings persisted even after assumptions about the prevalence of allergy and the prices of medications were changed. The {"}test strategy{"} increased the percentage of patients correctly diagnosed from 54 to 87{\%}. CONCLUSIONS: spIgE testing of children with respiratory and/or skin problems in primary care in Italy reduces overall costs to society. These cost savings mostly result from a reduction in the use of medications, particularly corticosteroids. The study indicates that spIgE testing of all children with respiratory and/or skin symptoms would be a cost-effective strategy.",
author = "Niklas Zethraeus and Petersson, {Carl Johan} and Massimiliano Dozzi and Borres, {Magnus P.} and Giulio Vignati and Alessandro Fiocchi",
year = "2010",
doi = "10.1186/1824-7288-36-61",
language = "English",
volume = "36",
pages = "61",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Health-care cost reduction resulting from primary-care allergy testing in children in Italy.

AU - Zethraeus, Niklas

AU - Petersson, Carl Johan

AU - Dozzi, Massimiliano

AU - Borres, Magnus P.

AU - Vignati, Giulio

AU - Fiocchi, Alessandro

PY - 2010

Y1 - 2010

N2 - BACKGROUND: Allergy places a considerable cost burden on society. Specific immunoglobulin E (spIgE) testing may improve the management of allergy patients. There is therefore a reason to quantify the economic consequences of the use of spIgE testing in the diagnosis of allergic conditions. METHODS: The expected costs of spIgE testing versus no-testing were calculated using a clinical decision model based on a prospective clinical trial performed in primary care. RESULTS: The expected costs per patient over 2 years decreased from 802 euros in the "no-test strategy" to 560 euros in the spIgE "test strategy". Cost savings persisted even after assumptions about the prevalence of allergy and the prices of medications were changed. The "test strategy" increased the percentage of patients correctly diagnosed from 54 to 87%. CONCLUSIONS: spIgE testing of children with respiratory and/or skin problems in primary care in Italy reduces overall costs to society. These cost savings mostly result from a reduction in the use of medications, particularly corticosteroids. The study indicates that spIgE testing of all children with respiratory and/or skin symptoms would be a cost-effective strategy.

AB - BACKGROUND: Allergy places a considerable cost burden on society. Specific immunoglobulin E (spIgE) testing may improve the management of allergy patients. There is therefore a reason to quantify the economic consequences of the use of spIgE testing in the diagnosis of allergic conditions. METHODS: The expected costs of spIgE testing versus no-testing were calculated using a clinical decision model based on a prospective clinical trial performed in primary care. RESULTS: The expected costs per patient over 2 years decreased from 802 euros in the "no-test strategy" to 560 euros in the spIgE "test strategy". Cost savings persisted even after assumptions about the prevalence of allergy and the prices of medications were changed. The "test strategy" increased the percentage of patients correctly diagnosed from 54 to 87%. CONCLUSIONS: spIgE testing of children with respiratory and/or skin problems in primary care in Italy reduces overall costs to society. These cost savings mostly result from a reduction in the use of medications, particularly corticosteroids. The study indicates that spIgE testing of all children with respiratory and/or skin symptoms would be a cost-effective strategy.

UR - http://www.scopus.com/inward/record.url?scp=77958131552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958131552&partnerID=8YFLogxK

U2 - 10.1186/1824-7288-36-61

DO - 10.1186/1824-7288-36-61

M3 - Article

VL - 36

SP - 61

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 1

ER -